Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | OGG1 | O15527 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182243 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL573354 | 0.98 | ALDH1A1 (0.63) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL272269 | 0.95 | ALDH1A1 (0.63) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL6694683 | 0.90 | ALDH1A1 (0.56) | ALDH1A1KMT2AKDM4ERAB9ARXFP1 | |
| SCHEMBL16121924 | 0.83 | ALDH1A1 (0.56) | ALDH1A1KMT2AKDM4ERAB9AMEN1 | |
| SCHEMBL23782301 | 0.83 | KDM4E (0.54) | ALDH1A1KMT2AKDM4ERAB9AGAA | |
| SCHEMBL26177824 | 0.83 | KDM4E (0.54) | ALDH1A1KMT2AKDM4ERAB9AGAA | |
| SCHEMBL23782299 | 0.83 | KDM4E (0.54) | ALDH1A1KMT2AKDM4ERAB9AGAA | |
| SCHEMBL2672312 | 0.83 | KMT2A (0.58) | ALDH1A1KMT2AKDM4ERAB9AMEN1 | |
| SCHEMBL3490122 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KMT2AKDM4ERAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | Sanford Burnham Prebys Medical Discovery Institute (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | Sanford Burnham Prebys Medical Discovery Institute | 2018-07-26 | — | — | US | disclosed |
| US-9926299-B2 | Inhibitors of bruton's tyrosine kinase | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9926299-B2 | Inhibitors of bruton's tyrosine kinase | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| US-9926299-B2 | Inhibitors of bruton's tyrosine kinase | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2018-03-27 | — | — | US | disclosed |
| WO-2016123392-A2 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
| WO-2016123392-A2 | PYRAZOLOPYRIMIDINES AS INHIBITORS OF GLUCOCORTICOID RECEPTOR TRANSLOCATION | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2925740-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | Centaurus Biopharma Co., Ltd. (CN) | 2015-10-07 | — | — | EP | disclosed |
| WO-2014082598-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014082598-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2014-06-05 | — | — | WO | disclosed |
| US-8354414-B2 | Substituted bicyclic pyrimidines | CEPHALON, INC (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | CEPHALON, INC. (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207140-A1 | Pyrazolopyrimidines as Inhibitors of Glucocorticoid Receptor Translocation | NR3C1, NR3C2, GRK3 | ALDH1A1 3369/4885KMT2A 3251/4885KDM4E 3498/4885 |
| US-20110053920-A1 | SUBSTITUTED BICYCLIC PYRIMIDINES | DPYD, P2RX5, P2RX7 | ALDH1A1 1266/4885KMT2A 3404/4885KDM4E 3148/4885 |
| US-20150299171-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | ALDH1A1 4268/4885KMT2A 1692/4885KDM4E 517/4885 |
| US-10272074-B2 | Inhibitors of glucocorticoid receptor translocation | NR3C1, NR3C2, GRK3 | ALDH1A1 3958/4885KMT2A 3527/4885KDM4E 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.